BFM
MYGN icon

Boothbay Fund Management’s Myriad Genetics MYGN Stock Holding History

Boothbay Fund Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,163
Closed -$87.1K – 2331
2025
Q4 		$87.1K Buy
+14,163
New +$103K ﹤0.01% 1757
2017
Q3 		– Sell
-15,843
Closed -$409K – 718
2017
Q2 		$409K Sell
15,843
-10,333
-39% -$219K 0.09% 312
2017
Q1 		$503K Buy
+26,176
New +$464K 0.09% 259
2015
Q3 		– Sell
-9,798
Closed -$333K – 548
2015
Q2 		$333K Buy
9,798
+1,051
+12% +$35.7K 0.13% 177
2015
Q1 		$310K Sell
8,747
-14,149
-62% -$506K 0.2% 128
2014
Q4 		$390K Buy
+22,896
New +$812K 0.3% 92

Other funds holding MYGN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boothbay Fund Management's MYGN Position: Q1 2026 in Review

Boothbay Fund Management sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 14,163 shares — an estimated $87.1K sold.

Boothbay Fund Management first reported a position in MYGN in Q4 2014 and held it in 6 quarters. The position peaked at $503K in Q1 2017. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Boothbay Fund Management reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 14,163 Myriad Genetics shares in Q1 2026, an estimated $87.1K.
  • Boothbay Fund Management first reported a position in Myriad Genetics in Q4 2014 and held it in 6 quarters.
  • Boothbay Fund Management's Myriad Genetics position peaked at $503K in Q1 2017.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.